Petros Grivas, MD, PhD - Achieving State-of-the-Art Care in Bladder Cancer in an Era of Innovative Therapeutic Solutions

Go online to PeerView.com/JKS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. In addition, the research on actionable targets has led to regulatory approval of the FGFR-targeted therapy, erdafitinib, for FGFR mutation–positive bladder tumors, as well as the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan. Further, novel bladder preservation opportunities and important combination approaches expand the therapeutic capacity across the disease spectrum available to patients with bladder cancer. In this PeerView activity, developed in collaboration with the Bladder Cancer Advocacy Network, a panel of leading bladder cancer experts will pair important analyses of the latest evidence on a new generation of therapeutics with practical insights that can be used to guide therapeutic decision-making in the clinic. This CME/MOC-certified activity highlights strategies for optimal care of patients with bladder cancer in light of current evidence on and indications for use of immune, targeted, and antibody-based therapies and guidance on safely integrating these agents into treatment plans. Upon completion of this CE activity, participants will be able to: Incorporate the latest clinical evidence, describe the current therapeutic roles and mechanistic rationales of novel systemic therapies, including immune checkpoint inhibitors, targeted therapies, and antibody–drug conjugates, across bladder cancer settings and patient populations (eg, localized or metastatic), Develop personalized treatment plans for patients with localized or metastatic bladder cancer that incorporate novel agents, updated guideline recommendations, and patient-, disease-, and treatment-specific factors, Employ evidence-based, collaborative strategies to mitigate and manage treatment-related AEs in patients receiving novel systemic therapies for bladder cancer.